Company: ChromaDex Corporation
Ticker: Nasdaq: CDXC
Sector: Consumer
Investor Contact: Ben Shamsian

ChromaDex Corporation News

News

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million for the three months ended June 30, 2024. LOS ANGELES - ChromaDex Corp....

ChromaDex to Join Russell 2000® Index

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide...

Skip to content